Nadex Advertisement
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Nabriva Therapeutics AG (NBRV)

Add NBRV Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 6/3/2016 8:04:16 PM - Followers: 1 - Board type: Free - Posts Today: 0

Nabriva Therapeutics AG Leberstrasse 20 Vienna, 1110 Austria Phone: 43 1 740 93 0 Fax: 43 1 740 93 1900 Website: Nabriva Therapeutics AG, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which has completed a Phase II clinical trial for acute bacterial skin and skin structure infections. The company is developing intravenous and oral formulations of lefamulin for the treatment of community-acquired bacterial pneumonia; and intends to develop lefamulin for additional indications other than pneumonia. It is also developing BC-7013, a topical pleuromutilin product candidate, which has completed a Phase 1 clinical trial. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics AG in 2007. Nabriva Therapeutics AG was incorporated in 2005 and is headquartered in Vienna, Austria.
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
NBRV News: Current Report Filing (8-k) 05:15 PM
NBRV News: Nabriva Therapeutics Appoints Francesco Maria Lavino as Chief Commercial Officer 07/11/2017 07:00:00 AM
NBRV News: Schedule 13g 07/10/2017 09:55:35 AM
NBRV News: Post-effective Amendment to a Previously Filed F-6. (f-6 Pos) 06/30/2017 02:19:40 PM
NBRV News: Amended Statement of Ownership: Solicitation (sc 14d9/a) 06/27/2017 05:22:59 PM
News News Alert: Current Report Filing (8-k) 07/21/2017 05:15:12 PM
#1   NBRV bearish 7.38 stocktrademan 06/03/16 08:04:16 PM